  |
The MedWatch July 2013 Safety Labeling Changes posting includes 34 products with safety labeling changes to the following sections: BOXED WARNINGS, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS and PATIENT PACKAGE INSERT.
The "Summary Page" provides a listing of product names and safety labeling sections revised:
http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm363949.htm
The following drugs had modifications to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS and PRECAUTIONS sections:
Depakene (valproic acid) Capsules and Oral Solution
Depakote (divalproex sodium) Delayed Release
Depakote ER (Extended Release) Tablets
Depakote Sprinkle Capsules (divalproex sodium coated particles in capsules)
Depacon (valproate sodium) Injection
Nizoral (ketoconazole) Tablets
Nucynta (tapentadol) Immediate-Release (IR) Oral Tablets
Prolia (denosumab)
Rapaflo (silodosin) Capsules
Sarafem (fluoxetine hydrochloride) Tablets
Agrylin (anagrelide hydrochloride) Capsules
Azor (amlodipine/olmesartan medoxomil) Tablets
Azulfidine EN-Tablets (sulfasalazine delayed release tablets, USP)
Bactrim and Bactrim DS Tablets
Benicar (olmesartan medoxomil)
Benicar HCT (olmesartan medoxomil/ hydrochlorothiazide) Tablets
Dulera (mometasone furoate/formoterol fumarate) Inhalation Aerosol
Elspar (asparaginase)
Geodon (ziprasidone) Capsules, Injection and Oral Suspension
Lupron Depot (Leuprolide Acetate for Depot Suspension)
MultiHance (gadobenate dimeglumine) Injection and MultiHance Multipack (gadobenate dimeglumine) Injection
Pentasa (mesalamine) Controlled-Release Capsules
Prozac (fluoxetine hydrochloride) Delayed Release Capsules
Symbyax (olanzapine and fluoxetine hydrochloride) Capsules
Tribenzor (olmesartan medoxomil/ amlodipine/ hydrochlorothiazide) Tablets
Vivitrol (naltrexone for extended-release injectable suspension)
Zelboraf (vemurafenib) Tablets
You are encouraged to report all serious adverse events and product quality problems to FDA MedWatch at www.fda.gov/medwatch/report.htm
Update your subscriptions, modify your e-mail address, or stop subscriptions at any time on your Subscriber Preferences Page. You will need to use your e-mail address to log in. If you have questions or problems with the subscription service, please contact support@xxxxxxxxxxxxxxx.
This service is provided to you at no charge by U.S. Food & Drug Administration (FDA).
| This email was sent to list-fda@xxxxxxxxxxx using GovDelivery, on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 800-439-1420 |  |
